Alcozyme Plus

Modern companion animal diets increasingly include diverse ingredients — plant proteins, legumes, complex carbohydrates and dietary fats — that demand a broader enzymatic repertoire than simple two-enzyme formulas can provide. When endogenous enzyme production is insufficient due to illness, exocrine pancreatic insufficiency (EPI), dietary complexity, inflammatory bowel disease or age-related decline, narrow enzyme coverage results in incomplete macronutrient breakdown, fermentation, gas, loose stools and poor nutrient bioavailability.

Alcozyme Plus is AlcoVet's advanced brand extension of Alcozyme, formulated with a five-enzyme complex — Alpha Galactosidase, Diastase, Bromelain, Pepsin and Lipase — to deliver complete macronutrient coverage across proteins, fats, starches and complex fermentable carbohydrates. It is indicated where standard dual-enzyme support is insufficient for the clinical presentation.

Each enzyme in Alcozyme Plus targets a distinct substrate class, ensuring no macronutrient passes through the gut undigested. Together they form a complete digestive matrix covering all four macronutrient groups.

Alcozyme and Alcozyme Plus both occupy Phase 1 (Stabilise) in the GI Therapy Ladder but differ in breadth and clinical indication. Use the table below to guide product selection.

Alcozyme Plus is indicated as advanced digestive enzyme support in the following clinical scenarios:

• Exocrine Pancreatic Insufficiency (EPI) — comprehensive enzyme replacement covering all macronutrients including dietary fats; critical for full EPI management in dogs and cats.
• Fat malabsorption and steatorrhoea — Lipase component supports fat emulsification and absorption in patients with steatorrhoeic presentations.
• Multi-ingredient and plant-rich diets — Alpha Galactosidase addresses fermentable oligosaccharides from legumes, peas and plant proteins in complex commercial diets.
• Inflammatory Bowel Disease (IBD) with digestive insufficiency — Bromelain's anti-inflammatory action combined with full enzyme coverage supports mucosal recovery and nutrient uptake.
• Post-pancreatitis and pancreatic recovery — exogenous enzyme supplementation to bridge the period of reduced pancreatic output following acute or chronic pancreatitis.
• Chronic flatulence and bloating — Alpha Galactosidase reduces colonic fermentation of undigested carbohydrates, directly addressing gas production.
• Senior patients with multi-enzyme decline — age-related reduction in pancreatic, gastric and intestinal enzyme output addressed comprehensively by the 5-enzyme profile.
• Post-gastroenteritis complex recovery — where standard Alcozyme monotherapy has not achieved adequate GI stabilisation within 3–5 days.
• Dietary transition in sensitive patients — enzymatic adaptation support during diet changes, reducing transition-related GI upset in breeds with known dietary sensitivity.

• Oral syrup — administer directly or mix into food, given immediately before or with meals
• Dosage adjusted by species, body weight, dietary fat content and clinical severity — refer to product labelling
• Compatible with concurrent probiotic and electrolyte therapy (Alcolyte Pro — GI Ladder Phase 2)
• In EPI and chronic pancreatic insufficiency, long-term ongoing use is appropriate under periodic veterinary review
• In post-pancreatitis recovery, continue until stable faecal consistency and appetite are re-established
• Palatable formulation — suitable for both dogs and cats; shake well before use
• Store in a cool, dry place below 25°C, away from direct sunlight

Each 5 ml of Alcozyme Plus Pet Syrup contains:

References support the scientific basis of this formulation. They do not constitute clinical recommendations. All therapeutic decisions should be made by a qualified veterinarian.

• 1 Steiner JM. Exocrine pancreatic insufficiency in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(2):355–367. doi:10.1016/j.cvsm.2012.01.006
• 2 Spillmann T. Exocrine pancreatic insufficiency in cats. Topics in Companion Animal Medicine. 2020. PubMed
• 3 Borda LJ, Wikramanayake TC. Bromelain — a literature review and discussion of its therapeutic applications. J Dermatol Dermatolog Surg. 2014. (Protease activity and anti-inflammatory properties).
• 4 German AJ. Chronic intestinal malabsorption in cats. Journal of Feline Medicine and Surgery. 2009;11(1):49–57.
• 5 Suarez FL et al. Reduction of intestinal gas following the consumption of legumes treated with Alpha Galactosidase. Am J Gastroenterol. 1999. (Alpha Galactosidase mechanism reference).
• 6 Simpson KW, Jergens AE. Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Vet Clin North Am Small Anim Pract. 2011;41(2):381–398. doi:10.1016/j.cvsm.2011.01.001
• 7 Wiberg ME, Nurmi AK, Westermarck E. Responses of dogs with exocrine pancreatic insufficiency to enzyme replacement therapy. Am J Vet Res. 1998;59(12):1503-1507. Demonstrates the necessity of broad-spectrum exogenous enzyme replacement, particularly lipase, in restoring nutritional status in EPI.
• 8 Guilford WG, Center SA, Strombeck DR, et al. Strombeck's Small Animal Gastroenterology. 3rd ed. Philadelphia: WB Saunders; 1996. Foundational text validating the staged physiological breakdown of macronutrients, supporting the rationale for multi-phase enzymes like pepsin (gastric) and bromelain/pancreatic enzymes (intestinal).